NE Regional Tile

NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, April 6

7:30am – 3:40pm 

Earn AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

REGISTER NOW

Location

Robert and Judi Prokop Newman Alumni Center
University of Miami
6200 San Amaro Dr, Coral Gables, FL 33146

Providers

Jointly Provided by Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and the North American Neuroendocrine Tumor Society

Syl-NET_lockup_3c_Full_Color-outline.png

Course Director

Dr. Aman Chauhan, MD - Miami, FL - Neuroendocrine Oncology - Book  Appointment

Aman Chauhan, MD, Sylvester Comprehensive Cancer Center

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

7:30am - 8:00am
8:00am - 8:10am
Registration and Breakfast
Welcome and Opening Remarks
    • Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program; Co-Director, Theragnostic Program, Sylvester Comprehensive Cancer Center
8:10am - 9:00am
Overview of Neuroendocrine Tumors
    • Words matter: NET is not NEC. Path 101
      Rhonda K. Yantiss, MD, Clinical Professor; Co-Chief of Anatomic Pathology Division; Co-Medical Director and CLIA Delegate of Anatomic Pathology Operations at UHealth; Director of Surgical Pathology Section, Sylvester Comprehensive Cancer Center
    • DOTATATE PET: who should get it and when?
      Russ A. Kuker, MD, Associate Professor of Clinical Radiology, Sylvester Comprehensive Cancer Center
    • How do we monitor NETs? Do novel biomarkers threaten radiologist job security?
      Thor R. Halfdanarson, MD, Professor of Oncology; Associate Professor of Medicine, Mayo Clinic
9:00am - 10:00am
Medical Management of NETs
    • Role of Somatostatin Analog in era of PRRT, is old still the gold?
      Renuka Iyer, MD, Professor of Oncology; Co- Leader Liver and Pancreas Tumor Program; Section Chief for Gastrointestinal Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center
    • Is PRRT the next best thing to sliced bread? The good, the bad and the ugly
      Simron Singh, MD, MPH, Associate Professor, University of Toronto; Provincial Head, Person Centered Care, Cancer Care Ontario; Medical Oncologist, Sunnybrook Odette Cancer Center/Susan Leslie Clinic for Neuroendocrine Cancers
    • Have Targeted Therapies overthrown Chemotherapy in NETs?
      Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program; Co-Director, Theragnostic Program, Sylvester Comprehensive Cancer Center
10:00am - 10:20am
Break
10:20am - 11:20am
Surgical Management and Sequencing
    • When to call your friendly surgeon for metastatic NETs?
      Tanaz Vaghaiwalla, MD, FACS, Assistant Professor of Surgery, Director Endocrine Surgery, The University of Tennessee Graduate School of Medicine
    • How do we sequence NET Systemic Therapies?
      Jonathan Strosberg, MD, Professor, Moffitt Cancer Center
11:20am - 12:00pm
Keynote
    • Federal Perspective on NET Drug Development Landscape and Future Directions
      Elise C. Kohn, MD, FAAAS, Head, Gynecologic Cancer Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute
12:00pm - 1:00pm
Lunch
1:00pm - 1:40pm
Lung NETs and Para/Pheos
    • Demystifying Thoracic neuroendocrine neoplasms. Key management differences in TC, AC, LCNEC, and SCLC
      Robert Ramirez, DO, Associate Professor of Medicine, Division of Hematology and Oncolocy, Department of Medicine, Vanderbilt University Medical Center
    • Practical guide to the management of Para-Pheos
      Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health
1:40pm - 2:20pm
Practical Problems and Solutions
    • Things you don’t read in books, a 30 year NET clinical experience: tips, pitfalls and some challenging cases
      Lowell B. Anthony, MD, FACP, Chief, Division of Medical Oncology, Co-director, Radiopharmaceutical Therapy Program, Markey Cancer Center, University of Kentucky
    • Financial Toxicity in NET patients; hidden facts and some solutions
      Taymeyah Al-Toubah, MPH, Senior Research Project Manager, Moffitt Cancer Center
2:20pm - 3:00pm
Allied Health Panel: Common patient concerns and how to navigate them
    • Moderators
      Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program; Co-Director, Theragnostic Program, Sylvester Comprehensive Cancer Center
      Boris G. Naraev, MD, PhD, FACP, Leader of the Neuroendocrine and Endocrine Cancers Program, Co-Leader, Theranostics Program, Tampa General Hospital Cancer Institute
    • Panelists
      Terri Pollock, DNP, APRN, FNP-C, PMHNP-BC, Advanced Practice Registered Nurse, Sylvester Comprehensive Cancer Center
      Anna Gonzalez, RDN, LDN, CNSC, Clinical Oncology Dietitian, Sylvester Comprehensive Cancer Center
      Mysti Motz, BSN, RN, Neuroendocrine Tumor Program Manager and Lutathera Coordinator, Sylvester Comprehensive Cancer Center
      Toni Bejarano, BSN, RN, Nurse Navigator, Sylvester Comprehensive Cancer Center
3:00pm - 3:30pm
Importance of Multidisciplinary NET Program and Latest Developments in Miami
    • Can we make PRRT Better? A sneak peek into the latest and greatest PRRT trials and overview of Sylvester Comprehensive Cancer Center’s NET and Theranostics Program
      Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program; Co-Director, Theragnostic Program, Sylvester Comprehensive Cancer Center
3:30pm - 3:40pm
Closing Remarks
    • Sylvester Comprehensive Cancer Center Associate Director

*Program is tentative and subject to change* 

REGISTER NOW

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.75 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.75 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 USD - MD, PharmD, Doctoral Level 
$35 USD - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 USD - MD, PharmD, Doctoral Level 
$50 USD - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before March 22, 2024. On or after March 23, 2024, no refund will be made.

The University of Miami and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.